Objective: To obtain descriptive safety and efficacy data for long-term levetiracetam therapy and to allow patients benefiting from add-on levetiracetam to continue treatment until the drug was available commercially. Methods: This long-term, noncomparative, open-label, follow-up study was conducted at 36 US sites. Patients with refractory partial epileptic seizures were eligible if they had benefited from add-on levetiracetam therapy in a previous study and wished to continue treatment. The levetiracetam dose was individualized over the range of 1000-4000 mg/day. Withdrawal of concomitant AEDs to allow levetiracetam monotherapy was permitted. Patients were evaluated every 12 weeks and followed for up to 4 years. Median total seizure frequency per week was the primary efficacy variable. Results: A total of 280 subjects, most of whom had refractory partial seizures with or without secondary generalization, were evaluated. Most were receiving either one (34.6%) or two (53.2%) concomitant antiepileptic drugs (AEDs) at entry. Overall, 199 (71.1%) subjects completed the study and 81 (28.9%) withdrew prematurely, most commonly due to loss or lack of efficacy or adverse events. The median total seizure frequency per week (0.7 at the selection visit) remained stable. The probability of being seizure-free during the first 12 weeks was 13.4% and 3.7% by week 216. Twentyfive (8.9%) subjects received levetiracetam monotherapy for at least 100 days. Levetiracetam was safe and well tolerated; the most common levetiracetam-related adverse events were dizziness (6.8%), convulsion (5.7%), and somnolence (5.0%). Conclusion: Efficacy and safety were maintained during long-term levetiracetam treatment of refractory partial seizures.
Introduction
Levetiracetam (Keppra 1 , UCB S.A.) is a novel antiepileptic drug (AED) that is indicated as adjunct therapy of partial-onset seizures in adults with epilepsy. 1, 2 The efficacy and safety of levetiracetam has been demonstrated in a series of clinical studies. In the three pivotal trials, add-on levetiracetam was significantly more effective than placebo in reducing seizure frequency in patients with refractory partial seizures. [3] [4] [5] In these studies, levetiracetam was initiated at a dose of 1000 mg/day and then increased to 2000 mg/day or 3000 mg/day given in two divided doses. In a fourth study that focused principally on safety and tolerability, levetiracetam was initiated at daily doses of 2000 mg or 4000 mg without titration in patients with refractory epilepsy of any type. 6 Treatment was well tolerated and again shown to be significantly more effective than placebo. The 4000-mg dose (but not 2000-mg dose) was associated with an increased incidence of somnolence, but this did not lead to more discontinuations.
Investigators have continued to follow patients who participated in these short-term clinical trials to assess long-term efficacy and tolerability. Patients who completed the pivotal placebo-controlled trial conducted in the United States (study N132) 4 and wished to continue (or switch from placebo to) levetiracetam therapy were eligible to enroll in a 54-week open-label follow-up study (study N140). After completion of study N140, patients were eligible to enroll in the long-term follow-up study reported herein. Also eligible for the present study were patients with refractory epilepsy who completed a 12-16-week open-label trial of add-on levetiracetam (study N153), 7 and patients with partial and/or tonicclonic seizures not fully controlled by monotherapy with maximum tolerated doses of phenytoin who completed a small 29-week open-label trial of levetiracetam as add-on treatment (study N143).
The objectives of the current study were to obtain descriptive safety and efficacy data for patients receiving long-term levetiracetam therapy at individualized doses of 1000-4000 mg/day, and to allow patients who had benefited from levetiracetam to continue with their treatment until the drug became available commercially.
Methods

Study design
This long-term, noncomparative, open-label, follow-up study was conducted at 36 US sites. Patients with partial epileptic seizures who had participated in a previous study of add-on levetiracetam therapy continued to receive levetiracetam and their existing AED therapy, if required, until the drug received marketing approval in the US and became available commercially. Duration of exposure varied, therefore, depending on the enrollment date. Subjects were evaluated every 12 weeks. At the investigators' discretion, the dose of levetiracetam was adjusted over the range of 1000-4000 mg/day to individualize therapy. Tapering and then withdrawal of concomitant AEDs was permitted to allow levetiracetam monotherapy.
This study was conducted according to the principles of the Declaration of Helsinki, and in accordance with Good Clinical Practices and applicable federal regulations. The protocol and statement of informed consent were approved by the Institutional Review Board at each study site.
Patients
Patients with epileptic seizures who completed a previous levetiracetam study (N132 and N140, N143, or N153) were eligible for the present study if they benefited from levetiracetam and wished to continue therapy. Most subjects (n = 183) had partialonset seizures with or without secondary generalization and entered this study after first completing a 38-week, double-blind, placebo-controlled, parallel-group study (N132) and then a 54-week, openlabel, follow-up study (N140). One subject entered directly after completing study N132. Ninety subjects with refractory epilepsy (partial or generalized) entered after completing a 12-16-week, open-label, multicenter study (N153), and six patients with partial and/or tonic-clonic seizures not fully controlled by maximum tolerated doses of phenytoin monotherapy entered after completing a 29-week, open-label interaction study (N143).
A total of 37 patients in study N153 had generalized epilepsy during the evaluation period of that study. Only US patients from N153 could be enrolled into the present study. Therefore, it is possible that a subset of US patients from the 37 patients in N153 enrolled in the present study. Fourteen patients experienced at least one generalized seizure during their participation in the current study. One hundred and seventy-two of the 179 patients who completed participation in study N153 entered a longterm follow-up study, with 90 patients entering the present study (the long-term study conducted in the US) and 82 patients entering study N129 (the longterm follow-up study conducted in Europe).
All subjects provided written informed consent before participating. For those under 18 years of age, the consent of both the patient and parent or legal guardian was required. Women of childbearing potential were required to use a medically acceptable method of birth control.
Subjects were excluded from the present study if they had a significant psychiatric disturbance, history of drug or alcohol abuse, rapidly progressive neurological disorder or cerebral tumor, degenerative cerebral disease, cerebrovascular accident, other clinically significant disease, leukopenia, or impaired renal or hepatic function. Patients with a history of severe allergic reactions or poor compliance to a study schedule or drug intake were also excluded, as were those participating in another ongoing clinical study and women who were pregnant or lactating. Drugs with central nervous system effects, such as neuroleptics, antidepressants, anxiolytics, psychostimulants, anticholinergics, tranquilizers, hypnotics, and narcotic analgesics, were not allowed.
Up to three concomitant AEDs were allowed. Treatment was discontinued when a subject withdrew consent, failed to comply with the protocol or drug treatment schedule, or became pregnant, or if in the investigator's opinion, it was warranted by an adverse event or by loss or lack of efficacy. To measure drug compliance, the number of tablets dispensed and returned was recorded in the case report form and dispensing log. The intake of study drug was required to be within 80-120% of the prescribed dose.
Selection and timing of doses
Levetiracetam was to be administered in two equal doses, once in the morning and once in the evening. The dose was continued from the previous study and then individualized at the discretion of the investigator. A daily dose of 4000 mg was initially allowed in the protocol, but an amendment to the protocol permitted this dose only if a careful review showed that the subject tolerated a 3000-mg dose during treatment for approximately 12 weeks, and the seizure frequency during levetiracetam therapy showed a trend that, in the investigator's judgment, suggested a dose increase above 3000 mg would benefit the patient. If the subject or investigator decided to discontinue levetiracetam, the drug was withdrawn gradually over a 2-8-week period. The schedule for withdrawal was defined by the investigator for each individual subject, with a step-down of up to 500 mg per week recommended in the protocol.
Concomitant AED therapy
Up to three concomitant AEDs from the following list were allowed: carbamazepine, ethotoin, topiramate, phenytoin, valproic acid, phenobarbital, primidone, clonazepam, ethosuximide, methsuximide, gabapentin, lamotrigine, and acetazolamide. Tiagabine was not permitted, because a commercial assay was not available when the study was started. Benzodiazepines used occasionally for seizure control were recorded as AEDs. The dose of the concomitant AEDs was to remain unchanged throughout the study, unless the investigator was obliged by circumstances of safety or efficacy to adjust the dose. If an investigator chose to substitute one concomitant AED for another, the ineffective AED was tapered and the new AED was uptitrated, most often simultaneously. In such cases, the substitution of one AED for another was considered to represent one concomitant AED. At any time during the study, the investigator could withdraw the concomitant AED to allow levetiracetam monotherapy.
Safety variables
Clinic visits were scheduled at 12-week intervals. At each visit, complete physical and neurological examinations as well as laboratory assessments, including hematology, blood chemistry, urine analysis, and plasma levels of levetiracetam and concomitant AEDs, were conducted. A serum pregnancy test was performed for all women, with the exception of those who were postmenopausal or surgically sterilized. Adverse events were identified from spontaneous reporting by the patient, clinical observations by the investigator, and questioning of the patient about their health. The nature and severity of all adverse events and their causal relationship to study drug were recorded by the investigator. Adverse events were then classified according to the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) dictionary. 8 A standard 12-lead electrocardiogram (ECG) was performed every 48 weeks and at the final study visit.
Efficacy variables
Subjects recorded the date, number, duration, and a description of all seizures on daily record cards. At each clinic visit, investigators reviewed the record cards and coded all seizures according to the International Classification of Epileptic Seizures. 9 The primary efficacy variable was defined as the median total seizure frequency per week. This measure included the sum of partial (type I), generalized (type II), and unclassifiable (type III) seizures. Secondary efficacy variables were the median partial seizure frequency per week and the occurrence of seizure-free intervals.
Statistical methods
Subjects who received at least one dose of levetiracetam were included in the intent-to-treat population. Due to the open-label design of this study, the efficacy and safety data were evaluated primarily using descriptive statistics. The total and partial seizure frequencies were calculated for each 12-week interval and for the entire duration each patient remained in the study. Because some subjects had much higher seizure frequency as compared to the majority of subjects, the median seizure frequency per week was used to summarize the data for the study population. A life-table survival analysis was used to estimate the probability of being continuously seizure-free for a specified time interval in two different ways. The first analysis was very conservative and focused on how long a patient who achieved seizure freedom at the start of the study remained seizure-free. As a consequence, subjects who had at least one seizure in the first 3 months of the study were considered to be failures, even if they became seizure-free later on. The second analysis was less restrictive and evaluated the duration of seizure-free periods that started at any time during the study. In this analysis, if subjects had multiple seizure-free periods, the last one (even if not the longest one) was selected.
Safety data were summarized descriptively over 6-month intervals. For adverse events, the number and percentage of patients was tabulated by body system, COSTART preferred term, severity, and relationship to treatment.
Results
Patient disposition and demographics
A total of 281 subjects enrolled in this study after completing a previous study of add-on levetiracetam therapy (Fig. 1 ). All were included in the intentto-treat population, except one patient who recorded few data points in the daily record card and was considered to be unreliable by the investigator. Of the remaining 280 patients, 199 (71.1%) subjects completed the study and 81 (28.9%) terminated the study prematurely. The most common reasons for premature termination were loss or lack of efficacy, adverse events, and withdrawn consent (Fig. 1) .
The study population ranged in age from 17.7 years to 72.5 years, with most being male and white (Table 1) . Three (1.1%) patients were aged 65 years or older. The etiology of epilepsy was unknown in 114 (40.7%) subjects, whereas it was caused by cranial trauma in 57 (20.4%) subjects and other factors in 59 (21.1%) subjects. Etiologies including asphyxia during birth, cerebral infection, congenital malformation, and genetic origin were reported by 580 B. Abou-Khalil, L. Schaich fewer than 8% of subjects. The following etiologies were also reported by a few patients: brain surgery, cerebral neoplasm, cerebrovascular accident, complications due to prematurity, and intrauterine viral infection. The mean age at epilepsy onset was 14.8 years, and the mean duration of epilepsy was 25.4 years. Because the vast majority of patients entering this study had partial-onset seizures with or without generalization, the median total and partial seizure frequency at the selection visit (computed on the 4-week period prior to selection) were similar--both were 0.7 per week. Most patients were receiving either one (97 subjects, 34.6%) or two (149 subjects, 53.2%) concomitant AEDs when they entered this study (Table 1) . Eleven (3.9%) subjects were receiving levetiracetam monotherapy. The most common concomitant AEDs were carbamazepine (131 subjects, 47.1%), lamotrigine (103 subjects, 36.8%), phenytoin (97 subjects, 34.6%), gabapentin (72 subjects, 25.7%), topiramate (59 subjects, 21.1%), and valproic acid and derivatives (56 subjects, 20.0%). By the end of the study period, the number of patients receiving levetiracetam monotherapy had increased to 25 (8.9%), but most were still receiving either one (93 subjects, 33.2%) or two (133 subjects, 47.5%) concomitant AEDs.
Mean treatment compliance during the entire evaluation period was 98.4%. Most patients (97.9%) had a compliance of between 80% and 120%.
Efficacy
Seizure frequency
The median total seizure frequency per week and the median partial-onset seizure frequency per week, both 0.7 at the selection visit, remained stable throughout the evaluation period (Fig. 2) . In the period between 2 years and 3.5 years, when about half of the study population was still available for analysis, the median total seizure frequency per week was 0.4-0.5, and the median partial-onset seizure frequency per week was 0.4. The observations for the 2-3.5-year period should be considered in the context of the decreased study population.
Subsets of patients with common minimal durations of exposure were also considered. The median total seizure frequency per week ranged from 0.6 to 0.7, 0.5 to 0.7, and 0.4 to 0.7, respectively, in evaluable patients treated for at least 1 year (225 subjects, 80.4%), 2 years (136 subjects, 48.6%), or 3 years (128 subjects, 45.7%). Similarly, the median partial-onset seizure frequency per week remained stable. It ranged from 0.6 to 0.7, 0.5 to 0.6, and 0.4 to 0.6 in subjects treated for at least 1 year (225 subjects, 80.4%), 2 years (136 subjects, 48.6%), or 3 years (128 subjects, 45.7%).
Seizure freedom
Seizure freedom was first determined for each subject from his or her enrollment in this study. The percentage of subjects who were continuously seizure-free during the first 12-week evaluation period was 13.4%. Thereafter, the cumulative percentage of seizure-free subjects gradually declined to 8.7% by week 48, 5.7% by week 108, 5.1% by week 168, and 3.7% by week 216. Duration of seizure freedom at any time during the study was also investigated (using the last seizure-free period of each subject if multiple periods existed). The probability of being seizure-free for at least 12 weeks was 29.5% and gradually decreased to 13.7% for at least 216 weeks.
Levetiracetam monotherapy
A total of 34 (12.1%) subjects received levetiracetam monotherapy for one or more intervals of at least 30 days, including the 11 patients who had entered the study on levetiracetam monotherapy. Nine (3.2%) subjects received monotherapy for 30- 100 days, seven (2.5%) for 101-365 days, seven (2.5%) for 1-2 years, and 11 (3.9%) for more than 2 years. Among the 25 subjects who received levetiracetam monotherapy for more than 100 days, most were started at a daily dose of 3000 mg (16 subjects, 64%) or 4000 mg (five subjects, 25%). The other four patients started levetiracetam monotherapy at doses of 1000-2500 mg. Data were not collected to allow a meaningful analysis of any changes in seizure type, frequency, or duration in these patients.
Safety
The study population received levetiracetam for a median of 670 days (range, 65-1469 days). Overall, 128 (45.7%) subjects were treated for more than 3 years, nine (3.2%) for >2 to 3 years, 91 (32.5%) for >1 to 2 years, and 52 (18.6%) for up to 1 year. A total of 275 (98.2%) of the 280 subjects experienced at least one study-emergent adverse event ( Table 2 ). The most common events (>20%) were accidental injury, infection, pain, headache, flu syndrome, convulsion, and dizziness, and for each of these, the investigator considered the majority to be unrelated to levetiracetam therapy. Despite the high incidence of infection and flu syndrome, none of these events was considered to be related to levetiracetam. Levetiracetam-related adverse events were reported for nearly half (131 subjects; 46.8%) of the study population. The highest incidence of such adverse events occurred in the nervous system (87 subjects, 31.1%), body as a whole (35 subjects, 12.5%), and digestive system (23 subjects, 8.2%). Only three levetiracetam-related adverse events 582 B. Abou-Khalil, L. Schaich Figure 2 Median total and partial-onset seizure frequencies per week over the evaluation period by cumulative duration of exposure (intent-to-treat population).
occurred at an incidence of 5% or higher: dizziness (19 subjects, 6.8%), convulsion (16 subjects, 5.7%), and somnolence (14 subjects, 5.0%). Serious adverse events were reported for 71 (25.4%) subjects during the evaluation period. The most common were convulsion (22 subjects, 7.9%), therapeutic procedure for epilepsy (11 subjects, 3.9%), accidental injury (eight subjects, 2.9%), and diagnostic procedure for epilepsy (six subjects, 2.1%). In nine subjects (3.2%), serious adverse events were considered to be related to study treatment.
Overall, 44 subjects (15.7%) experienced adverse events that led to a reduction in the total daily dose of levetiracetam or to withdrawal from the study; this reflects the development of any adverse event, not study-emergent events. A total of 20 patients (7.1%) discontinued treatment because of adverse events. These 20 included five subjects who died during the course of the study (two from myocardial infarction, one from metastatic ovarian cancer, one from sudden unexpected death in epilepsy, and the other from undetermined causes, possibly arrhythmia). All deaths were considered by the investigator to be unrelated to study treatment. Only three patients exited because of behavioral adverse experiences: one because of an aggressive reaction, one because of irritability, and one because of an intentional overdose.
The results of physical and neurological examinations as well as measurement of vital signs and ECG did not suggest any clinically meaningful changes over the course of the study. Laboratory parameters showed little change during the study, and in most cases, they remained within normal ranges. Changes in laboratory parameters of possible clinical significance included increases in gamma-glutamyltransferase (GGT; 18 subjects, 6.4%), decreases in hematocrit (14 subjects, 5.0%), decreases in neutrophil counts and increases in eosinophil counts (11 subjects, 3.9% for each), and decreases in white blood cell counts (13 subjects, 4.6%). With respect to the changes in GGT, it is important to note that the majority of subjects were receiving concomitant AEDs, which are known to induce this kind of abnormality. Thirteen subjects reported raised GGT values as adverse events, and of these, two were recorded as possibly related to study drug.
Discussion
This study was designed to allow patients who had benefited from levetiracetam therapy to continue with their treatment until the drug became available commercially, and to obtain descriptive safety and efficacy data for patients receiving long-term treatment at individualized doses of 1000-4000 mg/day. Many of the patients had participated in the pivotal US multicenter study of levetiracetam (study N132) and then in a 54-week, open-label follow-up (study N140). 4 When initially enrolled in the pivotal US study, these patients had uncontrolled partial seizures with or without secondary generalization for at least 2 years and had received at least two marketed AEDs either simultaneously or consecutively. Patients were randomly assigned to receive levetiracetam 1000 mg/day or 3000 mg/day or placebo as add-on therapy to one or two concomitant AEDs. At baseline, the median partial seizure frequency per week ranged from 1.8 to 2.5 in the three groups. Both doses of levetiracetam produced significantly greater median reductions in partial seizure frequency compared with placebo (32.5% and 37.1% versus 6.8%, P < 0.001). Moreover, a significantly greater percentage of patients treated with levetiracetam responded with at least 50% and 75% reductions in seizure frequency compared with placebo. Of the 294 randomized patients, 268 completed the study, 266 chose to continue in the 54-week open-label follow-up study, and 183 entered the present study.
The other major group of patients in the present study had epilepsy refractory to previous treatment Table 2 Most frequently reported study-emergent adverse events (!5% for levetiracetam-related events).
All adverse events n (%)
Levetiracetam-related a n (%) with at least two AEDs and had completed a 12-to 16-week open-label trial (study N153). 7 In that study, levetiracetam significantly reduced the median total seizure frequency from 2.25 at baseline to 1.1 during the evaluation period, with nearly half of the patients achieving 50% or greater reductions in seizure frequency. Of the 219 patients allocated to treatment, 172 who completed the evaluation period chose to continue adjunctive levetiracetam therapy, including 90 patients who entered the present study.
In the current study, treatment with individualized doses of levetiracetam continued to maintain the seizure control achieved in the previous trials. At baseline, the median seizure frequency per week was 0.7 for both total and partial-onset seizures, consistent with the marked preponderance of patients with partial-onset seizures in the study population. The median seizure frequency of the entire study population appeared to decline over time, but it is important to recognize that patients participated in this study for varying durations and were exposed to levetiracetam for varying lengths of time. The stability of seizure control with levetiracetam therapy was apparent when the subsets of patients who participated in the study for at least 1 year, 2 years, and 3 years were evaluated separately. For the subset of 128 patients who received treatment for at least 3 years, the median total seizure frequency per week was 0.7 at the selection visit and ranged from 0.4 to 0.7 during the third year, whereas the median partial seizure frequency per week was 0.6 at the selection visit and ranged from 0.4 to 0.7 in the third year. There were no signs of tolerance to levetiracetam.
The efficacy of levetiracetam was also evaluated by its ability to provide seizure freedom. This parameter was evaluated in two ways--seizure freedom from the start of the study, and seizure freedom lasting for a specific duration during the study. The probability of remaining seizure-free for the first 12 weeks of the study was 13.4%, which then declined gradually over time. By 4 years, the probability of being seizure-free since the beginning of the study was 3.7%. In the two pivotal studies of levetiracetam in which a daily dose of 3000 mg was used, approximately 8.2% of the patients randomized to the 3000-mg arms were seizure-free during the 12-14-week evaluation of add-on therapy.
3,4 The higher probability seen during the first 12-week interval of the present study is likely attributed to the nature of the patient population, which included those who had already shown a benefit of add-on levetiracetam therapy. In the current study, the probability of having a seizure-free interval of 12 weeks was 29.5%, and the probability of having a seizure-free interval of 4 years was 13.7%. This latter analysis, however, was influenced by the varying lengths of time that patients participated in the study.
The pivotal trial by Ben-Menachem et al. 3 showed that patients with refractory partial seizures who responded to levetiracetam with a 50% or greater reduction in seizure frequency could be successfully converted to levetiracetam monotherapy. In that study, 49 of 69 eligible patients were converted successfully to monotherapy, and this group showed a median percentage reduction in partial seizure frequency of 73.8% during monotherapy compared with baseline. The results of the present study extend these short-term findings by showing that some patients can be maintained on long-term levetiracetam monotherapy. Eleven (3.9%) subjects entered the current study while receiving levetiracetam monotherapy, and overall, 25 (8.9%) patients received monotherapy for more than 100 days during the study. Eleven (3.9%) subjects received monotherapy for more than 2 years.
Recently, Ben-Menachem et al. 10 reviewed the data collected for all 1422 patients with refractory epilepsy treated with levetiracetam for 6-54 months during the development program. Overall, the number of concomitant AEDs could be reduced in 205 patients (14.4%), and 79 (5.5%) were taking levetiracetam monotherapy at the end of follow-up. It also appeared that long-term adverse events were similar in nature to those seen with short-term levetiracetam therapy in the pivotal trials. [3] [4] [5] [6] Long-term tolerability similar to that seen in the short-term clinical trials, and sustained efficacy, have also been reported by Ben-Menachem and Gilland 11 in patients who are generally not eligible for clinical trials due to factors, such as mental retardation or concomitant psychiatric disorders.
In a long-term study of patients with refractory disease, treatment-emergent adverse events are to be expected. In most cases, however, these adverse events have been considered unrelated to levetiracetam therapy. In the current study, the most common levetiracetam-related adverse events were dizziness, ''convulsion'', and somnolence, consistent with the previous studies in which these patients participated 4, 7 as well as with other controlled clinical trials of add-on levetiracetam. 3, 5, 6 In general, the incidence of adverse events with levetiracetam in previous studies was unrelated to dose. Most adverse events appear to develop during uptitration, suggesting that these events are triggered by the initial exposure to the drug but lessen over time.
The physical and neurological examinations, which were conducted every 12 weeks, did not reveal any clinically meaningful changes over the course of the study. In patients with epilepsy, GGT levels are often elevated. The increase is usually attributed to the liver enzyme induction seen with AED therapy. Unlike other AEDs, levetiracetam does not induce liver enzyme activities. 12 Review of the changes in GGTshowed no correlation with exposure to levetiracetam, and in most cases, these changes were transient and improved as levetiracetam treatment continued.
In summary, the present study demonstrates that the efficacy and tolerability of add-on levetiracetam therapy are maintained during long-term treatment. Patients received individualized doses that were adjusted based on the clinical judgment of the investigator. Median seizure frequency remained stable throughout the 4-year evaluation period, with some patients being free of seizures for significant intervals during the study. Additionally, some patients were maintained effectively on levetiracetam monotherapy.
